Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P9YT | ISIN: ES0169501022 | Ticker-Symbol: PMRA
Tradegate
24.06.25 | 19:32
81,15 Euro
+2,59 % +2,05
1-Jahres-Chart
PHARMA MAR SA Chart 1 Jahr
5-Tage-Chart
PHARMA MAR SA 5-Tage-Chart
RealtimeGeldBriefZeit
79,2579,3511:06
79,2579,3511:06

Aktuelle News zur PHARMAMAR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiXFRA CAPITAL ADJUSTMENT INFORMATION - 24.06.2025138Das Instrument GI8 CA39032G1046 GREAT EAGLE GOLD CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 24.06.2025 und ex Kapitalmassnahme am 25.06.2025 The instrument GI8 CA39032G1046 GREAT EAGLE GOLD...
► Artikel lesen
FrPHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 16 and 19 June 2025. Ending of the Share Buy-back Program and resumption of the liquidity agreement.2
18.06.PHARMA MAR, S.A.: It is reported that all proposed resolutions submitted by the Board to the General Shareholders' Meeting have been approved.2
18.06.PHARMA MAR, S.A.: The Company informs about the dividend payment charged to unrestricted reserves.2
18.06.PHARMA MAR, S.A.: Attached is a copy of the presentation to shareholders to be made at the General Shareholders' Meeting of Pharma Mar by the Chairman and by the Chief Financial Officer of the Company.1
16.06.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 9 June and 13 June 2025.2
10.06.PHARMA MAR, S.A.: Pharma Mar announces that the FDA grants Priority Review for Zepzelca® (lurbinectedin) and atezolizumab (Tecentriq®) combination in Extensive Stage Small Cell Lung Cancer.11
09.06.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 2 June and 6 June 2025.3
PHARMAMAR Aktie jetzt für 0€ handeln
03.06.PharmaMar präsentiert auf der ASCO dass Zepzelca® (lurbinectedin) in Kombination mit Atezolizumab (Tecentriq®) das Überleben als Erstlinien-Erhaltungstherapie bei kleinzelligem Lungenkrebs323Madrid (ots/PRNewswire) - - Die Erstlinien-Erhaltungskombinationstherapie verringerte das Risiko eines Fortschreitens der Krankheit oder des Todes um 46%, mit einer medianen Gesamtüberlebenszeit von...
► Artikel lesen
03.06.PHARMA MAR, S.A.: Pharma Mar presents in ASCO positive results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer.5
03.06.PharmaMar presents at ASCO that the Zepzelca(lurbinectedin) and atezolizumab (Tecentriq) combination significantly improves survival as first-line maintenance therapy for extensive-stage small cell lung cancer302First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from...
► Artikel lesen
02.06.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 26 May and 30 May 2025.2
26.05.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 19 May and 23 May 2025.2
26.05.ASCO 25: Jazz, PharmaMar reveal SCLC survival data5
21.05.PHARMA MAR, S.A.: The Company has submitted EU marketing authorization application for lurbinectedin in combination with atezolizumab in first-line maintenance therapy for extensive-stage small cell lung cancer.3
19.05.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 12 May and 16 May 2025.2
19.05.PHARMA MAR, S.A.: The Company announces that its partner Adium Pharma S.A. has received approval for commercialization for Zepzelca® (lurbinectedina) in Argentina.3
12.05.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 5 May and 9 May 2025.3
06.05.PHARMA MAR, S.A.: The Company sends notice of the Ordinary General Shareholders' Meeting and proposed resolutions.3
05.05.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 28 April and 2 May 2025.3
Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1